Please login to the form below

Not currently logged in
Email:
Password:

Beleodaq

This page shows the latest Beleodaq news and features for those working in and with pharma, biotech and healthcare.

AZ signs two more deals in cancer immunotherapy

AZ signs two more deals in cancer immunotherapy

The latter is in the same class as Merck &Co's Zolinza (vorinostat), Novartis' Farydak (panobinostat) and Spectrum Pharmaceuticals' Beleodaq (belinostat), which are approved for various haematological cancers.

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics